Correction of neutropenia with rHuG-CSF after loss of response to rHuGM-CSF following autologous bone marrow transplant.
We describe a patient who presented with graft failure following autologous BMT, with an initial response of the neutrophil count to rHuGM-CSF but eventual loss of this response. Subsequently, this patient responded to rHuG-CSF. This could be explained by the fact that rHuG-CSF stimulates both early and late myeloid progenitor cells whereas rHuGM-CSF stimulates mainly the intermediate myeloid progenitor cells. This finding suggests that rHuG-CSF should be investigated for the treatment of patients with graft failure following ABMT.
Boulad
F
F
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Gillio
A
A
Small
T N
TN
Bonilla
M A
MA
Philips
P
P
Ruggiero
M
M
Emanuel
D
D
Ghavimi
F
F
Kernan
N A
NA
D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014182:Transplantation, Autologous
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor